| http://www.w3.org/ns/prov#value | - In neuroscience, we are developing compounds to address conditions such as Alzheimer's disease, Parkinson's, schizophrenia, pain and MS. A Phase III study of daclizumab, a next-generation biologic being evaluated in MS, is currently underway.
|
